|

Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

RECRUITINGSponsored by Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Actively Recruiting
SponsorCenters for Medicare and Medicaid Services/ Coverage and Analysis Group
Started2023-07-06
Est. completion2028-06-30
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06058234

Summary

The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.

Exclusion Criteria:

* none

Conditions3

Alzheimer's DiseaseMild Alzheimer's DiseaseMild Cognitive Impairment (MCI) Due to Alzheimer's Disease

Locations1 site

Centers for Medicare and Medicaid Services
Baltimore, Maryland, 21244
CMS CAG410-786-2281CMS_caginquiries@cms.hhs.gov

Browse More Trials

Alzheimer's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.